Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

BACKGROUND: Recombinant activated factor VII (rFVIIa, NovoSeven(®)) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX. OBJECTIVE: To review the evidence supporting the use of rFVIIa for the treatment of patients with congenital blee...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Pär I, Ostrowski, Sisse R
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915535/
https://www.ncbi.nlm.nih.gov/pubmed/20689697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915535/
https://www.ncbi.nlm.nih.gov/pubmed/20689697

Ejemplares similares